孤立性慢性难治性皮肤癣菌感染:遗传、免疫与临床评估
该前瞻性研究纳入5910例浅表皮肤真菌感染患者中的11例慢性难治性皮肤癣菌感染(CRDI)患者,病程超过5年且对至少三种口服抗真菌药无效。55%(6/11)存在免疫异常,包括单基因免疫缺陷、获得性免疫缺陷和孤立性IL-17缺乏;多数患者持续口服抗真菌治疗仅部分有效,停药后复发。
要点
- CRDI在浅表皮肤真菌感染中罕见(11/5910),病程长且广泛累及皮肤和甲。
- 超过半数CRDI患者存在免疫异常,建议进行遗传和免疫学评估。
- 多数患者需长期或终身口服抗真菌治疗,停药后易复发。
核心结论
- CRDI是浅表皮肤真菌感染中的罕见情况,患者常存在潜在免疫缺陷。
- 对CRDI患者应考虑遗传和免疫学评估以识别免疫缺陷。
- 治疗可能需要长期或终身口服抗真菌药物。
研究设计与样本
- 前瞻性研究,纳入5910例浅表皮肤真菌感染患者中11例孤立性CRDI患者(10男,91%),平均病程26.4年(SD 8.7)。
- 纳入标准:感染持续>5年且对至少三种口服抗真菌药无效。
- 进行全外显子测序、IL-17定量和淋巴细胞亚群分析。
主要发现
- 11例患者平均累及5.6个(SD 1.4)皮肤和甲部位。
- 55%(6/11)存在免疫异常:3例单基因免疫缺陷突变(CARD9和FOXN1),1例获得性免疫缺陷(Good综合征),2例孤立性IL-17缺乏。
- 10/11例对持续口服抗真菌治疗部分有效,仅1例停药后完全缓解。
临床怎么用
- 对病程长、多种口服抗真菌药无效的浅表皮肤真菌感染患者,应怀疑CRDI。
- 建议对CRDI患者进行遗传和免疫学评估以排查免疫缺陷。
- 管理上可能需要长期或终身口服抗真菌治疗以控制感染。
局限性
- 样本量小(仅11例),可能限制统计效能和普遍性。
- 研究为前瞻性单中心设计,结果需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic recalcitrant dermatophyte infection (CRDI) remains poorly understood, with limited research on its genetic, immunological and treatment aspects. OBJECTIVES: To investigate the genetic and immunological profiles, clinical characteristics and treatment outcomes in otherwise healthy patients with CRDI. METHODS: This was a prospective study of patients with isolated superficial dermatophyte infections persisting for > 5 years and refractory to at least three oral antifungal agents. Whole-exome sequencing, interleukin (IL)-17 quantification and lymphocyte subset analysis were performed. RESULTS: Of 5910 patients with superficial cutaneous fungal infections, 11 (10 men; 91%) with a mean (SD) disease duration of 26.4 (8.7) years were included in this study. All patients presented with extensive dermatophytosis, involving a mean (SD) of 5.6 (1.4) skin and nail sites. Immune alterations were identified in 55% (n = 6/11) of the patients, including three with monogenic immunodeficiency mutations (CARD9 and FOXN1), one with acquired immunodeficiency (Good syndrome) and two with isolated IL-17 deficiencies. Most patients (n = 10/11) showed a partial clinical response to continuous oral antifungal therapy, while only one patient remained a complete responder after discontinuing treatment. CONCLUSIONS: CRDI is a rare condition in patients with superficial cutaneous fungal infections. Genetic and immunological evaluation for immunodeficiency should be considered in patients with CRDI. Management may require prolonged or lifelong oral antifungal therapy. Fungal skin infections are common. They usually respond well to treatment. Some people have persistent infections that do not get better with standard medications. This condition is named ‘chronic recalcitrant dermatophyte infection’ (CRDI). In this study, we aimed to understand why these infections occur and how they can be better treated. We looked at whether problems with the immune system cause some patients to develop CRDI. We also assessed potential treatments. Of 5910 patients with fungal skin infections, 11 had CRDI. These patients had infections for over 5 years. They had not got better after trying at least three different medicines. We performed genetic and immune system tests to look for possible underlying causes. We found that CRDI is rare. It affects a tiny fraction of patients with fungal skin infections. More than half of our patients had problems with their immune systems. This suggests that immune system problems have a role in persistent infections. Most patients improved with continuous treatment. But, their infections came back when the treatment stopped. Patients with CRDI may have underlying problems with their immune system that make it harder for them to fight infections. Genetic and immunological testing can help identify such problems. Some patients may need long term or lifelong treatment to keep the skin infection under control. Understanding CRDI better can help doctors identify at-risk patients. It will also help improve treatment strategies for this challenging condition.
引用
- Galili E, Barzilai A, Lev A, et al. Genetic, immunological and clinical assessment of isolated chronic recalcitrant dermatophytosis: a prospective study. Br J Dermatol. 2025. PMID: 40663635. doi:10.1093/bjd/ljaf269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。